These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 12597158)

  • 1. [Evolution of the parameters indicating response to drug therapy: from regression to complete control of the disease and the symptoms].
    Cascinu S; Camisa R; D'Angelo A; Salvagni S
    Tumori; 2002; 88(6):A7-9. PubMed ID: 12597158
    [No Abstract]   [Full Text] [Related]  

  • 2. JAMA Oncology Patient Page. The Evolution of a Cancer.
    West HJ; Jin JO
    JAMA Oncol; 2015 Sep; 1(6):850. PubMed ID: 26247697
    [No Abstract]   [Full Text] [Related]  

  • 3. PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development.
    Hansen AR; Siu LL
    JAMA Oncol; 2016 Jan; 2(1):15-6. PubMed ID: 26562503
    [No Abstract]   [Full Text] [Related]  

  • 4. Predictive biomarkers: identification and verification.
    Yeatman TJ
    J Clin Oncol; 2009 Jun; 27(17):2743-4. PubMed ID: 19332709
    [No Abstract]   [Full Text] [Related]  

  • 5. Introducing the BECT (biologically enhanced cytotoxic treatment) concept in cancer treatment.
    Bernier J; Bourhis J
    Ann Oncol; 2005 Nov; 16(11):1722. PubMed ID: 16087695
    [No Abstract]   [Full Text] [Related]  

  • 6. [Rationales for the integration of molecular and conventional therapies].
    Tortora G; Ciardiello F
    Tumori; 2002; 88(6):A9-13. PubMed ID: 12597159
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of epithelial-mesenchymal transition and cancer stem cells.
    Topcul M; Cetin I
    J BUON; 2016; 21(2):312-9. PubMed ID: 27273939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer stem cell targeted therapy: progress amid controversies.
    Wang T; Shigdar S; Gantier MP; Hou Y; Wang L; Li Y; Shamaileh HA; Yin W; Zhou SF; Zhao X; Duan W
    Oncotarget; 2015 Dec; 6(42):44191-206. PubMed ID: 26496035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers.
    Singh N; Krishnakumar S; Kanwar RK; Cheung CH; Kanwar JR
    Drug Discov Today; 2015 May; 20(5):578-87. PubMed ID: 25433305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biomarkers in solid tumors].
    Nagy Z
    Magy Onkol; 2013 Mar; 57(1):56-62. PubMed ID: 23573523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of access to targeted cancer therapy.
    Burki TK
    Lancet Oncol; 2015 Oct; 16(13):e482. PubMed ID: 26321211
    [No Abstract]   [Full Text] [Related]  

  • 13. Pragmatic issues in biomarker evaluation for targeted therapies in cancer.
    de Gramont A; Watson S; Ellis LM; Rodón J; Tabernero J; de Gramont A; Hamilton SR
    Nat Rev Clin Oncol; 2015 Apr; 12(4):197-212. PubMed ID: 25421275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using biomarkers in drug development.
    Workman P
    Clin Adv Hematol Oncol; 2006 Oct; 4(10):736-9. PubMed ID: 17099630
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictive biomarkers for cancer therapy with PARP inhibitors.
    Michels J; Vitale I; Saparbaev M; Castedo M; Kroemer G
    Oncogene; 2014 Jul; 33(30):3894-907. PubMed ID: 24037533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP inhibitors in ovarian and other cancers.
    Plummer R
    Clin Adv Hematol Oncol; 2015 May; 13(5):285-7. PubMed ID: 26352770
    [No Abstract]   [Full Text] [Related]  

  • 17. Proteomic profiling predicts drug response to novel targeted anticancer therapeutics.
    Lin F; Li Z; Hua Y; Lim YP
    Expert Rev Proteomics; 2016; 13(4):411-20. PubMed ID: 26954459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia-inducible factor-1 as a therapeutic target in cancer.
    Tang CM; Yu J
    J Gastroenterol Hepatol; 2013 Mar; 28(3):401-5. PubMed ID: 23173651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ectokinases as novel cancer markers and drug targets in cancer therapy.
    Yalak G; Vogel V
    Cancer Med; 2015 Mar; 4(3):404-14. PubMed ID: 25504773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delivering on the promise of precision cancer medicine.
    Berger MF; Van Allen EM
    Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.